A M Walker1. 1. Epidemiology Resources, Inc., Newton Lower Falls, Massachusetts 02162-1450, USA.
Abstract
OBJECTIVE: To quantify the risk of symptomatic hepatic injury associated with nonsteroidal antiinflammatory drugs (NSAIDs). METHODS: Five population-based studies were summarized to evaluate information on more than 1,000,000 patients using NSAIDs. RESULTS: The risk of clinically apparent liver injury was approximately 1 case per 10,000 patient-years of NSAID use. Only sulindac, associated with a 5-10-fold higher incidence of hepatic injury, differed significantly from other NSAIDs. Patients using diclofenac showed no higher incidence of serious liver disease than did patients using other NSAIDs. CONCLUSION: Symptomatic hepatic effects attributable to most NSAIDs are extremely rare and usually mild.
OBJECTIVE: To quantify the risk of symptomatic hepatic injury associated with nonsteroidal antiinflammatory drugs (NSAIDs). METHODS: Five population-based studies were summarized to evaluate information on more than 1,000,000 patients using NSAIDs. RESULTS: The risk of clinically apparent liver injury was approximately 1 case per 10,000 patient-years of NSAID use. Only sulindac, associated with a 5-10-fold higher incidence of hepatic injury, differed significantly from other NSAIDs. Patients using diclofenac showed no higher incidence of serious liver disease than did patients using other NSAIDs. CONCLUSION: Symptomatic hepatic effects attributable to most NSAIDs are extremely rare and usually mild.
Authors: Wei Zou; Sachin S Devi; Erica Sparkenbaugh; Husam S Younis; Robert A Roth; Patricia E Ganey Journal: Toxicol Sci Date: 2008-12-12 Impact factor: 4.849
Authors: Vincent Lo Re; Dena M Carbonari; James D Lewis; Kimberly A Forde; David S Goldberg; K Rajender Reddy; Kevin Haynes; Jason A Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley Journal: Am J Med Date: 2015-11-17 Impact factor: 4.965